New Combination Drug for Depression.
The American journal of nursing April 1, 2023 DOI: 10.1097/01.naj.0000925488.72453.63 via PubMed
Summary
AI-generated from the abstractAuvelity, a combination of dextromethorphan and bupropion, is approved for major depressive disorder in adults. It carries a boxed warning about increased risk of suicidal thoughts and behaviors in pediatric and young adult patients, similar to other antidepressants. Seizures are possible, especially at higher doses. Common side effects include dizziness, nausea, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, hyperhidrosis, anxiety, constipation, decreased appetite, and insomnia.
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Population | Adults with major depressive disorder |
| Intervention | Dextromethorphan-bupropion |
| Key finding | Auvelity is approved for treating major depressive disorder in adults but carries risks of suicidal thoughts in younger patients and seizures at higher doses. |
Abstract
Auvelity, an extended-release fixed combination of dextromethorphan and bupropion, is approved for the treatment of major depressive disorder in adults.Like all antidepressants, dextromethorphan-bupropion carries a boxed warning that it may increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Seizures can also occur and are more likely at higher doses.The most common adverse effects of dextromethorphan-bupropion include dizziness, nausea, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, hyperhidrosis, anxiety, constipation, decreased appetite, and insomnia.